ORIC PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
ORIC PHARMACEUTICALS INC. - More news...
ORIC PHARMACEUTICALS INC. - More news...
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
- ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
- ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
- ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
- ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
- ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
- Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
- ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates